OGFR

Summary

OGFR (opioid growth factor receptor, HGNC:15768) is a protein-coding gene on chromosome 20q13.33, encoding Opioid growth factor receptor (Q9NZT2). Receptor for opioid growth factor (OGF), also known as Met-enkephalin.

The protein encoded by this gene is a receptor for opioid growth factor (OGF), also known as [Met(5)]-enkephalin. OGF is a negative regulator of cell proliferation and tissue organization in a variety of processes. The encoded unbound receptor for OGF has been localized to the outer nuclear envelope, where it binds OGF and is translocated into the nucleus. The coding sequence of this gene contains a polymorphic region of 60 nt tandem imperfect repeat units. Several transcripts containing between zero and eight repeat units have been reported.

Source: NCBI Gene 11054 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 133 total
• GTEx eGene: eQTL in 46 tissues, sQTL in 9 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 0.98 (unconstrained)
• MANE Select transcript: NM_007346
• Notable: 133 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15768
Approved symbol	OGFR
Name	opioid growth factor receptor
Location	20q13.33
Locus type	gene with protein product
Status	Approved
Aliases	7-60
Ensembl gene	ENSG00000060491
Ensembl biotype	protein_coding
OMIM	606459
Entrez	11054

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 4 nonsense_mediated_decay

MANE Select: ENST00000290291

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1, TSL 3: 1

ENST00000290291, ENST00000370461, ENST00000450048, ENST00000892717, ENST00000892718, ENST00000967036, ENST00000974343, ENST00001038345, ENST00001038347, ENST00001038348

RefSeq mRNA: 1 — MANE Select: NM_007346 NM_007346

CCDS: CCDS13504

Canonical transcript exons

ENST00000290291 — 7 exons

Exon	Start	End
ENSE00001210611	62812230	62814000
ENSE00001280931	62811462	62811610
ENSE00002438831	62809585	62809663
ENSE00002440273	62810499	62810565
ENSE00002499201	62808247	62808325
ENSE00002507804	62807537	62807605
ENSE00002728822	62804835	62805030

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 96.51.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 43.8234 / max 1160.2352, expressed in 1819 samples.

Highest expression (Bgee): granulocyte, monocyte, mononuclear cell, leukocyte, sural nerve.

Genetic regulation across tissues (GTEx eQTL / sQTL)

OGFR is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 46 tissues and its splicing (sQTL) in 9 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 55 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Thyroid	eqtl	4.5e-46	-0.41	20:62812518:C:G
Nerve Tibial	eqtl	1.9e-36	-0.39	20:62797792:G:A
Testis	eqtl	3.2e-23	-0.52	20:62806674:C:A
Adipose Subcutaneous	eqtl	2.1e-22	-0.26	20:62814091:G:T
Stomach	eqtl	4.6e-18	-0.39	20:62812284:G:A
Lung	eqtl	2.2e-17	-0.19	20:62797792:G:A
Heart Atrial Appendage	eqtl	2.6e-17	-0.24	20:62812518:C:G
Pituitary	eqtl	2.9e-17	-0.39	20:62812518:C:G
Colon Transverse	eqtl	2.3e-16	-0.28	20:62806674:C:A
Brain Nucleus accumbens basal ganglia	eqtl	2.7e-16	-0.35	20:62809683:G:A
Breast Mammary Tissue	eqtl	1.2e-15	-0.32	20:62812284:G:A
Adipose Visceral Omentum	eqtl	3.4e-15	-0.26	20:62793436:A:T
Pancreas	eqtl	3.4e-14	-0.34	20:62812518:C:G
Brain Cerebellar Hemisphere	eqtl	1.2e-13	-0.30	20:62812518:C:G
Brain Cerebellum	eqtl	1.3e-13	-0.41	20:62812518:C:G
Esophagus Mucosa	eqtl	1.5e-13	-0.23	20:62812284:G:A
Testis	sqtl	1.6e-13	-0.59	20:62806454:C:T
Brain Cortex	sqtl	1.0e-12	-0.80	20:62801376:C:T
Skin Not Sun Exposed Suprapubic	eqtl	4.2e-12	-0.20	20:62814091:G:T
Spleen	eqtl	5.3e-12	-0.38	20:62812518:C:G

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
185759	43.8234	1819

Top tissues by expression

showing 100 of 289 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	96.51	gold quality
monocyte	CL:0000576	95.76	gold quality
mononuclear cell	CL:0000842	95.59	gold quality
leukocyte	CL:0000738	95.55	gold quality
sural nerve	UBERON:0015488	95.06	gold quality
right frontal lobe	UBERON:0002810	94.66	gold quality
right lobe of liver	UBERON:0001114	94.64	gold quality
endometrium epithelium	UBERON:0004811	94.44	gold quality
spleen	UBERON:0002106	93.95	gold quality
right lung	UBERON:0002167	93.27	gold quality
right uterine tube	UBERON:0001302	93.16	gold quality
tibial nerve	UBERON:0001323	92.85	gold quality
cingulate cortex	UBERON:0003027	92.76	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.67	gold quality
anterior cingulate cortex	UBERON:0009835	92.67	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.50	gold quality
mucosa of stomach	UBERON:0001199	92.46	gold quality
upper lobe of left lung	UBERON:0008952	92.37	gold quality
apex of heart	UBERON:0002098	92.24	gold quality
left ovary	UBERON:0002119	92.14	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.14	gold quality
muscle layer of sigmoid colon	UBERON:0035805	92.14	gold quality
right lobe of thyroid gland	UBERON:0001119	92.10	gold quality
adenohypophysis	UBERON:0002196	92.08	gold quality
frontal pole	UBERON:0002795	92.04	gold quality
lower esophagus muscularis layer	UBERON:0035833	91.96	gold quality
lower esophagus	UBERON:0013473	91.95	gold quality
left lobe of thyroid gland	UBERON:0001120	91.93	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	91.93	gold quality
paraflocculus	UBERON:0005351	91.92	gold quality
blood	UBERON:0000178	91.84	gold quality
lower esophagus mucosa	UBERON:0035834	91.82	gold quality
middle frontal gyrus	UBERON:0002702	91.74	gold quality
right ovary	UBERON:0002118	91.68	gold quality
body of stomach	UBERON:0001161	91.67	gold quality
metanephros cortex	UBERON:0010533	91.49	gold quality
left uterine tube	UBERON:0001303	91.37	gold quality
endocervix	UBERON:0000458	91.21	gold quality
amygdala	UBERON:0001876	91.08	gold quality
upper lobe of lung	UBERON:0008948	91.05	gold quality
pituitary gland	UBERON:0000007	90.97	gold quality
small intestine	UBERON:0002108	90.92	gold quality
body of uterus	UBERON:0009853	90.86	gold quality
type B pancreatic cell	CL:0000169	90.85	silver quality
pancreatic ductal cell	CL:0002079	90.81	silver quality
ectocervix	UBERON:0012249	90.78	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	90.73	gold quality
omental fat pad	UBERON:0010414	90.73	gold quality
thyroid gland	UBERON:0002046	90.70	gold quality
peritoneum	UBERON:0002358	90.70	gold quality
parotid gland	UBERON:0001831	90.57	gold quality
fundus of stomach	UBERON:0001160	90.46	gold quality
skin of leg	UBERON:0001511	90.44	gold quality
mucosa of transverse colon	UBERON:0004991	90.39	gold quality
minor salivary gland	UBERON:0001830	90.24	gold quality
olfactory bulb	UBERON:0002264	90.21	silver quality
saliva-secreting gland	UBERON:0001044	90.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.01	gold quality
transverse colon	UBERON:0001157	90.00	gold quality
prefrontal cortex	UBERON:0000451	89.98	gold quality
putamen	UBERON:0001874	89.96	gold quality
adipose tissue of abdominal region	UBERON:0007808	89.95	gold quality
stromal cell of endometrium	CL:0002255	89.91	gold quality
neocortex	UBERON:0001950	89.87	gold quality
stomach	UBERON:0000945	89.86	gold quality
skin of abdomen	UBERON:0001416	89.86	gold quality
nucleus accumbens	UBERON:0001882	89.63	gold quality
caudate nucleus	UBERON:0001873	89.56	gold quality
frontal cortex	UBERON:0001870	89.54	gold quality
frontal lobe	UBERON:0016525	89.54	gold quality
esophagus	UBERON:0001043	89.45	gold quality
cerebellar hemisphere	UBERON:0002245	89.39	gold quality
right coronary artery	UBERON:0001625	89.33	gold quality
left coronary artery	UBERON:0001626	89.27	gold quality
cerebellar cortex	UBERON:0002129	89.25	gold quality
vena cava	UBERON:0004087	89.22	silver quality
coronary artery	UBERON:0001621	89.12	gold quality
body of pancreas	UBERON:0001150	89.09	gold quality
hypothalamus	UBERON:0001898	89.00	gold quality
Brodmann (1909) area 10	UBERON:0013541	88.86	gold quality
mouth mucosa	UBERON:0003729	88.82	gold quality
lymph node	UBERON:0000029	88.81	gold quality
popliteal artery	UBERON:0002250	88.81	gold quality
tibial artery	UBERON:0007610	88.81	gold quality
forebrain	UBERON:0001890	88.79	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	88.79	gold quality
cerebral cortex	UBERON:0000956	88.71	gold quality
telencephalon	UBERON:0001893	88.66	gold quality
gastrocnemius	UBERON:0001388	88.64	gold quality
aorta	UBERON:0000947	88.60	gold quality
left adrenal gland cortex	UBERON:0035825	88.57	gold quality
sigmoid colon	UBERON:0001159	88.56	gold quality
ganglionic eminence	UBERON:0004023	88.55	gold quality
hindlimb stylopod muscle	UBERON:0004252	88.47	gold quality
ascending aorta	UBERON:0001496	88.46	gold quality
descending thoracic aorta	UBERON:0002345	88.44	gold quality
triceps brachii	UBERON:0001509	88.43	silver quality
thoracic aorta	UBERON:0001515	88.41	gold quality
brain	UBERON:0000955	88.36	gold quality
central nervous system	UBERON:0001017	88.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.34

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 80 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Postcentral gyrus	tissue	46.2
Spleen	tissue	36.0	medium
Pituitary gland	tissue	35.8
Hippocampus	tissue	35.7	low
Caudate putamen	tissue	34.9
Vagina	tissue	32.8	low
Bone marrow	tissue	32.6	high
Cerebellum	tissue	31.2	medium
Choroid plexus	tissue	29.5
Locus coeruleus	tissue	28.2
Salivary gland	tissue	27.2	low
Nucleus accumbens	tissue	27.1
Duodenum	tissue	26.8	medium
Frontal cortex	tissue	25.8
Appendix	tissue	25.3	low
Lymph node	tissue	24.9	medium
Cerebral cortex	tissue	24.6	medium
Small intestine	tissue	24.6	low
Somatosensory cortex	tissue	24.6
Hippocampal formation	tissue	23.5
Liver	tissue	22.9	high
Basal ganglia	tissue	22.4	low
Pons	tissue	22.2
Midbrain	tissue	22.2
Temporal cortex	tissue	22.2
Thalamus	tissue	21.9
Ventral forebrain	tissue	21.4
Lung	tissue	21.1	medium
Septum	tissue	21.1
Putamen	tissue	20.9
Entorhinal cortex	tissue	20.9
Spinal cord	tissue	20.8
Prefrontal cortex	tissue	20.5
Motor cortex	tissue	20.5
Stomach 1	tissue	20.4	medium
Superior colliculi	tissue	20.0
Pancreas	tissue	19.8	medium
Medulla oblongata	tissue	19.7
Occipital cortex	tissue	19.7
Skin 1	tissue	19.4	low
Hypothalamus	tissue	19.0
Retrosplenial and cingulate cortex	tissue	18.8
Substantia nigra	tissue	18.4
Insular cortex	tissue	18.1
Retrosplenial cortex	tissue	18.0
Adipose tissue	tissue	17.9	low
Amygdala	tissue	17.8
Ovary	tissue	16.9	low
Skeletal muscle	tissue	16.7	low
Periaqueductal gray	tissue	16.7
Retina	tissue	16.0
Olfactory bulb	tissue	15.7
Tonsil	tissue	14.2	medium
Thymus	tissue	14.1
Endometrium 1	tissue	14.0	low
Seminal vesicle	tissue	13.3	medium
Prostate	tissue	12.8	medium
Adrenal gland	tissue	12.8	medium
Placenta	tissue	12.6	medium
Colon	tissue	12.5	high

Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Precentral gyrus (55.0), Area parastriata, superior (51.9), Temporo-occipital transitional zone (50.2), Orbitofrontal gyrus, anterior (47.2), Inferior parietal lobule (47.0).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F4

miRNA regulators (miRDB)

Targeting OGFR by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

18 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-2115-3P	99.31	69.68	2026
HSA-MIR-892C-5P	99.16	70.56	2116
HSA-MIR-6768-3P	99.14	67.38	1319
HSA-MIR-1245B-5P	98.88	66.55	576
HSA-MIR-3142	98.88	66.09	529
HSA-MIR-506-5P	98.02	67.41	1065
HSA-MIR-4456	97.50	64.88	1678
HSA-MIR-874-5P	96.93	63.92	1014
HSA-MIR-1178-5P	95.83	64.12	504

Functional genomics

gnomAD constraint: pLI 4.97e-05, LOEUF 0.984, missense Z -0.32 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000290291 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
20:62,804,860–62,813,189	760 / 736.0	1.03	no
20:62,813,190–62,813,555	72 / 181.8	0.40	no
20:62,813,556–62,813,646	45 / 38.0	1.19	no

Literature-anchored findings (GeneRIF, showing 15)

• Gene therapy to reinstate more OGFr and enhance OGFr function, could serve as a useful treatment for inhibiting tumor progression in head and neck cancers. (PMID:16685459)
• Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers (PMID:16820893)
• These data indicate that the OGF receptor is integral to cell replication of SCCHN, and support treatment modalities that amplify OGFr in order to decrease the growth of these neoplasias. (PMID:17273790)
• supports opioid growth factor receptor (OGFr) gene function as a regulator of cell proliferation that impacts on tumorigenic expression, and suggest that molecular and pharmacological manipulation of OGFr may prevent or delay human pancreatic cancer. (PMID:18636152)
• Results indicate that both p16(INK4a) and p21(WAF1/CIP1) are required for the opioid growth factor (OGF)-OGF receptor axis to inhibit cell proliferation in normal cells. (PMID:18923142)
• the regulation of cell proliferation by the OGF-OGFr axis is dependent on nucleocytoplasmic translocation and reliant on the integrity of two NLSs in OGFr to interact with transport receptors. (PMID:19244545)
• Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. (PMID:19297547)
• Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. (PMID:19675283)
• OGF and OGFR are present in follicular-derived thyroid cancers, and that OGF serves in a inhibitory manner to maintain homeostasis of cell proliferation. (PMID:19835629)
• These data are the first to report that theOGFr system is a native biological regulator of cell proliferation in Hepatocellular carcinoma (PMID:19923357)
• OGF-OGFr axis is a determinant of the progression of human ovarian cancer (PMID:22328595)
• The OGF-OGFr axis may be a feasible target for treatment of cancer of the ovary (i) in a prophylactic fashion, (ii) following cytoreduction or (iii) in conjunction with standard chemotherapy for additive effectiveness (PMID:23856908)
• The blockade of OGF signaling by MNTX releases cells from their arrest and boosts the effect of Doc (PMID:25853862)
• Morphine interacts with OGFR and may suppress lung cancer proliferation and progression. (PMID:27167686)
• beta-endorphin and opioid growth factor as biomarkers of physical ability in multiple sclerosis. (PMID:33677409)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	ogfr2	ENSDARG00000024815
danio_rerio	ogfr	ENSDARG00000037837
danio_rerio	ogfr1	ENSDARG00000099409
danio_rerio		ENSDARG00000103677
mus_musculus	Ogfr	ENSMUSG00000049401
rattus_norvegicus	Ogfr	ENSRNOG00000009355

Paralogs (1): OGFRL1 (ENSG00000119900)

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Xenopus tropicalis	A2VCV0	70.6%	Diamond
Simkania negevensis Z	F8L8G5	35.8%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
OGFR-AS1	ncRNA	101409261
TCFL5	protein-coding	10732
SNORA117	snoRNA	109623463
DIDO1	protein-coding	11083
COL9A3	protein-coding	1299
LINC00659	ncRNA	100652730
MRGBP	protein-coding	55257
NTSR1-AS1	ncRNA	139281656
NTSR1	protein-coding	4923

Protein

Protein identifiers

Opioid growth factor receptor — Q9NZT2 (reviewed: Q9NZT2)

Alternative names: Protein 7-60, Zeta-type opioid receptor

All UniProt accessions (3): A0A0A0MRN5, Q4VXW3, Q9NZT2

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for opioid growth factor (OGF), also known as Met-enkephalin. Seems to be involved in growth regulation.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Highly expressed in the heart and liver, moderately in skeletal muscle and kidney and to a lesser extent in brain and pancreas. Expressed in fetal tissues including liver and kidney.

Similarity. Belongs to the opioid growth factor receptor family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NZT2-1	1	yes
Q9NZT2-2	2

RefSeq proteins (1): NP_031372* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006757	OGF_rcpt	Domain
IPR006770	OGF_rcpt_rpt	Repeat
IPR039574	OGFr	Family

Pfam: PF04664, PF04680

UniProt features (53 total): sequence conflict 15, modified residue 14, compositionally biased region 8, repeat 7, region of interest 4, sequence variant 2, chain 1, short sequence motif 1, splice variant 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NZT2-F1	63.00	0.34

Human Protein Atlas

Protein class: Predicted intracellular proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm

Antibody reliability (HPA): IH supported · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (14)

Type	Positions
N-acetylmethionine	1
Phosphoserine	299, 315, 349, 361, 378, 382, 403, 420, 484, 537, 557, 617, 637

Function

Pathways and Gene Ontology

Reactome pathways

0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

MSigDB gene sets: 135 (showing top): MORF_RAB5A, GOBP_GROWTH, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP, RODRIGUES_NTN1_TARGETS_DN, AMIT_EGF_RESPONSE_120_HELA, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_13, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, GOMF_PEPTIDE_RECEPTOR_ACTIVITY, SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC, IVANOVA_HEMATOPOIESIS_EARLY_PROGENITOR, GOBP_CELL_GROWTH, GOBP_REGULATION_OF_GROWTH, SANSOM_APC_MYC_TARGETS, GARY_CD5_TARGETS_UP

GO Biological Process (1): regulation of cell growth (GO:0001558)

GO Molecular Function (3): opioid growth factor receptor activity (GO:0140625), protein binding (GO:0005515), signaling receptor activity (GO:0038023)

GO Cellular Component (3): nucleus (GO:0005634), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

9 GO namespaces:

Category	Terms
cellular anatomical structure	2
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
peptide receptor activity	1
binding	1
molecular transducer activity	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

showing 15 of 502 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OGFR	PENK	P01210	920
OGFR	OPRD1	P41143	451
OGFR	OPRM1	P35372	434
OGFR	IVNS1ABP	Q9Y6Y0	360
OGFR	OR6C65	A6NJZ3	275
OGFR	OR6K6	Q8NGW6	266
OGFR	PNOC	Q13519	242
OGFR	OR56A1	Q8NGH5	241
OGFR	UBAP1L	F5GYI3	236
OGFR	NAAA	Q02083	235
OGFR	CYB5D1	Q6P9G0	235
OGFR	PIGBOS1	A0A0B4J2F0	215
OGFR	PGBD4	Q96DM1	205
OGFR	ASB14	A6NK59	203
OGFR	ASB15	Q8WXK1	203

IntAct

Human interaction partners of OGFR in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

5 partners by confidence:

Partner	Interaction type	MIscore	Records
TERF2IP	physical association	0.510	2
CDK4	physical association	0.400	1
GPR182	physical association	0.370	1
TERF1	physical association	0.370	1
GSTK1	physical association	0.000	1

BioGRID (63 interactions; top human partners by supporting records): CDK4 (Affinity Capture-MS; 3 records), PRKCE (Affinity Capture-MS; 2 records), TGIF2LY (Affinity Capture-MS; 2 records), AAR2 (Affinity Capture-MS), ARIH2 (Affinity Capture-MS), ATG5 (Proximity Label-MS), BRCA1 (Affinity Capture-MS), CCNF (Affinity Capture-MS), CDC37 (Co-fractionation), CLIC1 (Affinity Capture-MS), CLUAP1 (Affinity Capture-MS), DDX58 (Affinity Capture-RNA), E2F4 (Affinity Capture-MS), EIF2B2 (Co-fractionation), EZH2 (Affinity Capture-MS)

Disease & clinical

Genetic variants

Variant evidence for OGFR: 133 ClinVar records (0 pathogenic / likely pathogenic); 4 GWAS associations.

ClinVar

133 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	99
Likely benign	25
Benign	0

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 36 predictions of 603):

Position(s)	Effect	Δscore	Sites
20:62805031–62805032	donor_loss	1.0000	3
20:62808236–62808237	acceptor_gain	1.0000	2
20:62808245–62808246	acceptor_loss	1.0000	4
20:62808327	donor_loss	1.0000
20:62809574	acceptor_gain	1.0000
20:62811460–62811461	acceptor_loss	1.0000	6
20:62811611–62811612	donor_loss	1.0000	5
20:62812228–62812229	acceptor_loss	1.0000	6
20:62805031–62805032	donor_loss	0.9900	2
20:62807535–62807536	acceptor_loss	0.9900	6

AlphaMissense

840 missense substitutions predicted likely pathogenic (of 4,406 scored), across 188 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
F135	8	0.978	0.996
F96	8	0.971	0.998
H128	8	0.964	0.990
F284	8	0.963	0.998
H208	8	0.956	0.985
D71	8	0.955	0.976
F177	8	0.953	0.998
N143	8	0.952	0.998
F257	8	0.943	0.993
F103	8	0.923	0.988
D255	8	0.909	0.971
N209	8	0.906	0.990
N99	8	0.896	0.996
F236	8	0.884	0.988
F157	8	0.872	0.984
S252	8	0.871	0.990
D7	8	0.838	0.897
W133	7	0.989	0.998
F259	7	0.979	0.994
W286	7	0.977	0.995

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Rectum Adenocarcinoma (validation)	favorable	0.000298

Disease associations

OMIM: gene MIM:606459 | disease phenotypes:

GWAS associations

4 associations:

Study	Trait	p-value
GCST012226_440	Waist circumference adjusted for body mass index	7e-14
GCST007919_21	Creatinine levels	3e-8
GCST012231_212	A body shape index	3e-8
GCST007917_5	Estimated glomerular filtration rate	2e-7

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105797 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.71	Kd	195.6	nM	CHEMBL5653589
6.71	ED50	195.6	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 14 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148912: Binding affinity to human OGFR incubated for 45 mins by Kinobead based pull down assay	kd	0.1956	uM

CTD chemical–gene interactions

46 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance, affects expression	3
Estradiol	increases expression, increases phosphorylation	2
Ozone	affects cotreatment, decreases expression, increases abundance, affects expression	2
Tretinoin	increases expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
testosterone enanthate	affects expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	decreases expression	1
lead acetate	increases expression	1
cupric chloride	increases expression	1
coumarin	decreases phosphorylation	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
beta-methylcholine	affects expression	1
perfluoro-n-nonanoic acid	decreases expression	1
ICG 001	decreases expression	1
bisphenol B	increases expression	1
bisphenol S	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Bortezomib	decreases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Arsenic	increases expression, increases abundance	1
Atrazine	increases expression	1
Caffeine	decreases phosphorylation	1
Cannabidiol	decreases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4044464	Binding	Antagonist activity at OGFR in human SKOV3 cells assessed as increase in cell growth at 10 uM after 24 hrs by hemacytometric method	Selective opioid growth factor receptor antagonists based on a stilbene isostere. — *Bioorg Med Chem*

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1ZI	Abcam HeLa OGFR KO	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for OGFR across ~30M SureChEMBL compounds — explore on Sugi Predict.